Clinical Trial Update: Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the efficacy and safety of rimonabant 20 mg daily versus placebo for smoking cessation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED